Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNS396
- Development stage
- Preclinical
- Lead developer
- Genoscience Pharma
- Modality
- Small Molecules
01
Overview
GNS396 is a small molecule FMS-like tyrosine kinase 3 (FLT3) inhibitor being developed by Genoscience Pharma for the treatment of acute myeloid leukemia (AML). The drug is designed to target cancer stem cells by acting as a lysosomotropic agent that disrupts lysosomal functions and inhibits autophagy pathways, thereby depriving cancer cells of essential nutrients. GNS396 was intended to be combined with chemotherapy drugs like cytarabine to simultaneously target both tumorigenic and non-tumorigenic leukemia cell populations, with the goal of overcoming cellular heterogeneity and plasticity in AML to potentially increase remission time and reduce relapse frequency.
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on GNS396.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNS396.